EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy ; volume:14 ; number:1 ; day:26 ; month:11 ; year:2024 ; pages:1-14 ; date:12.2024
Scientific reports ; 14, Heft 1 (26.11.2024), 1-14, 12.2024
- Urheber
-
Djermane, Rania
Nieto, Celia
Vega, Milena A.
Valle, Eva M. Martín del
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-80879-0
- URN
-
urn:nbn:de:101:1-2502112103129.875407959260
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Djermane, Rania
- Nieto, Celia
- Vega, Milena A.
- Valle, Eva M. Martín del
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
Diazo transfer at polydopamine
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial
Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
Diazo transfer at polydopamine
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial
Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
Diazo transfer at polydopamine
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial